Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools


You are here: Home / Members / Ronald C. Chen
Ronald C. Chen

Ronald C. Chen

  • MD, MPH
  • Cancer Prevention and Control
  • Urologic Oncology Program

  • Assistant Professor
  • UNC-Chapel Hill
  • 919-966-0400
  • 101 Manning Drive, CB 7512 Chapel Hill, NC 27599
  • Link to CV or NIH biosketch

Area of Interest

Primary clinical interests are in 1) genitourinary cancers and 2) Cyberknife radiation.

Cyberknife is an exciting new technology, and could represent a more accurate way to deliver radiation because of an ability to ?track? the movement of the tumor (target) during radiation. The University of North Carolina is one of the few academic centers in the United States with a Cyberknife and a clinical trial for prostate cancer patients (4 radiation treatments) is being offered.

Primary research interest involves the long-term outcomes of prostate cancer patients and survivors. This includes bringing new prostate cancer treatments to the clinic, clinical trials, and studying/comparing the efficacy and long-term quality of life effects of current treatments (including surgery and radiation) for prostate cancer.

The long-term quality of life impact of prostate cancer treatments is increasingly recognized as an important consideration in the decision-making process for a patient. For men with localized prostate cancer, most become long-term survivors, but the treatments they chose and received may leave long-lasting quality of life effects and symptoms. Surgery, external beam radiation, and brachytherapy are all accepted standard treatments for localized prostate cancer, but they cause distinctly different short-term and long-term side effects. One of Dr. Chen?s main research interests is in studying the quality of life of prostate cancer survivors, and to bring this information to clinical use by counseling patients prior to choosing treatment.

Awards and Honors

  • 1996 Barry M. Goldwater Scholar
  • 1999 Highest Distinction (equivalent to summa cum laude), University of Kansas
  • 2000 Harvard Medical School PASTEUR Fellow -Patient-Associated Science: Training, Education, Understanding, and Research
  • 2001 Leopold Schepp Foundation Scholarship
  • 2001 Doris Duke Clinical Research Fellow
  • 2004 Cum laude, Harvard Medical School
  • 2006 Travel grant, American Society for Therapeutic Radiology and Oncology Health Services/Outcomes Research in Oncology Symposium
  • 2007 CaPSURE Scholar
  • 2008 Radiation Therapy Oncology Group (RTOG) Meeting Travel Grant
  • 2009 ASCO Cancer Foundation Merit Award
  • 2009 ASCO/AACR Methods in Clinical Research (Vail Workshop)